Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease
Rhea-AI Summary
Opus Genetics (Nasdaq: IRD) announced completion of patient enrollment in its registrational Phase 3 trial of OPGx-LCA5, an investigational gene therapy for LCA5-associated inherited retinal disease. The study design was developed with the U.S. FDA and aligned through the Rare Disease Evidence Principles (RDEP) program.
According to Opus Genetics, the one-time subretinal therapy is being evaluated for safety and efficacy using a six-month run-in period where patients serve as their own control. Dosing is expected to begin in Q4 2026, with topline six-month efficacy data targeted by year-end 2027, potentially supporting a Biologics License Application with 12-month durability data submitted during review. OPGx-LCA5 holds FDA Rare Pediatric Disease, Orphan Drug, and RMAT designations and may qualify for a Rare Pediatric Disease Priority Review Voucher upon approval.
Positive
- Phase 3 enrollment completed for OPGx-LCA5 registrational trial
- Dosing start guided for Q4 2026 with topline data by end 2027
- Trial design aligned with FDA through Rare Disease Evidence Principles program
- Multiple FDA designations: Rare Pediatric Disease, Orphan Drug, and RMAT
- Potential Priority Review Voucher upon approval of OPGx-LCA5
Negative
- Topline six-month efficacy data not expected until end of 2027
- Biologics License Application remains contingent on future Phase 3 results
News Explained
Enrollment is complete, but the OPGx-LCA5 Phase 3 trial remains before gene-therapy dosing: participants are completing the six-month run-in, with dosing expected in the fourth quarter of
Key Figures
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 06 | FDA trial alignment | Positive | -3.8% | FDA alignment established the Phase 3 registrational trial design for OPGx-LCA5. |
| May 07 | Cohort enrollment | Positive | +1.9% | Cohort 1 enrollment was completed in the Phase 1/2 OPGx-BEST1 study. |
| May 04 | FDA program acceptance | Positive | -0.4% | OPGx-LCA5 entered the FDA Rare Disease Evidence Principles program. |
| Feb 27 | Initial clinical data | Positive | +15.9% | Initial OPGx-BEST1 data reported safety findings and efficacy signals. |
| Feb 25 | FDA application acceptance | Positive | -3.9% | FDA accepted the supplemental application for phentolamine ophthalmic solution. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive clinical-trial announcements produced mixed reactions, with 2 aligned responses and 3 divergences.
Key Terms
biologics license application regulatory
rare disease evidence principles regulatory
regenerative medicine advanced therapy regulatory
subretinal administration medical
run-in period medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Topline six-month efficacy data expected by end of 2027
Phase 3 study follows FDA alignment on registrational trial design through Rare Disease Evidence Principles (RDEP) program
Opus Genetics may submit a BLA based on 6-month efficacy data, with 12-month durability data provided during review
RESEARCH TRIANGLE PARK, N.C., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that the last patient has been enrolled in its registrational Phase 3 clinical trial evaluating OPGx-LCA5, the Company’s investigational gene therapy for LCA5-associated inherited retinal disease.
Completion of enrollment marks a significant milestone in the development of OPGx-LCA5 and follows the program’s acceptance into the U.S. Food and Drug Administration’s (FDA) Rare Disease Evidence Principles (RDEP) program in May 2026. The Phase 3 study was designed in collaboration with the FDA to support a potential Biologics License Application (BLA) for what could become the first approved therapy for patients living with LCA5-associated inherited retinal disease.
“Achieving full enrollment in our registrational Phase 3 trial is a significant milestone for the OPGx-LCA5 program and reflects the dedication of participating patients and families, our clinical investigators, and our team,” said George Magrath, M.D., Chief Executive Officer, Opus Genetics. “With enrollment now complete, we remain on track to initiate dosing in the fourth quarter of 2026, report topline data by the end of 2027, and continue advancing OPGx-LCA5 to bring the first potential treatment to patients with LCA5-associated inherited retinal disease.”
The registrational Phase 3 trial is evaluating the safety and efficacy of a one-time subretinal administration of OPGx-LCA5 in patients with genetically confirmed LCA5-associated inherited retinal disease. Consistent with the Company’s RDEP discussions with the FDA, the study incorporates innovative evidence-generation approaches appropriate for an ultra-rare disease, including a six-month run-in period in which patients serve as their own control. Participants are currently completing the run-in period, and the Company expects to initiate dosing of OPGx-LCA5 in the fourth quarter of 2026, with topline data expected by the end of 2027.
OPGx-LCA5 has received Rare Pediatric Disease, Orphan Drug, and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA and has been accepted into the FDA’s Rare Disease Evidence Principles (RDEP) program.
The Company continues to expect that OPGx-LCA5 may qualify for a Rare Pediatric Disease Priority Review Voucher upon approval, representing a potentially significant strategic asset.
About OPGx-LCA5
OPGx-LCA5 is designed to address a form of Leber congenital amaurosis (LCA) due to biallelic mutations in the LCA5 gene (LCA5), which encodes the lebercilin protein. LCA5-associated inherited retinal disease is an early-onset severe inherited retinal dystrophy. Studies in patients with this mutation have reported evidence for the dissociation of retinal architecture and visual function in this disease, suggesting an opportunity for therapeutic intervention through gene augmentation. OPGx-LCA5 uses an adeno-associated virus 8 (AAV8) vector to precisely deliver a functional LCA5 gene to the outer retina. OPGx-LCA5 has received Rare Pediatric Disease, Orphan Drug, and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA and has been accepted into the FDA’s Rare Disease Evidence Principles (RDEP) program. OPGx-LCA5 is currently being evaluated in a Phase 1/2/3 clinical trial.
About Opus Genetics
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RDH12, MERTK, RHO, CNGB1 and NMNAT1. The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com.
Forward-Looking Statements
This press release contains certain statements that are not statements of historical fact and are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements related to the anticipated timing of topline data from the OPGx-LCA5 Phase 3 clinical trial, clinical development, clinical results, preclinical data, and future plans for OPGx-LCA5 and expectations regarding us, our business prospects, and our results of operations and are subject to certain risks and uncertainties posed by many factors and events that could cause our actual business, prospects and results of operations to differ materially from those anticipated by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those described under the heading “Risk Factors” included in our most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2025, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, and in our other filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. These forward-looking statements are based upon our current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “aim,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “strive,” “will,” “would” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. We undertake no obligation to revise any forward-looking statements in order to reflect events or circumstances that might subsequently arise.
Contacts:
Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com
Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
Source: Opus Genetics, Inc.
